Jiangsu Hengrui Medicine
600276.SS
#471
Rank
A$73.43 B
Marketcap
A$11.06
Share price
-1.71%
Change (1 day)
9.60%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2025 (TTM): A$0.19

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is A$0.18. In 2024 the company made an earnings per share (EPS) of A$0.19 an increase over its 2023 EPS that were of A$0.14.

EPS history for Jiangsu Hengrui Medicine from 2000 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$0.19-1.46%
2024A$0.1942.43%
2023A$0.148.77%
2022A$0.13-20.62%
2021A$0.16-26.59%
2020A$0.2227.24%
2019A$0.1728.41%
2018A$0.1320.04%
2017A$0.1131.21%
2016A$0.0839011.46%
2015A$0.0752736.27%
2014A$0.0552419.77%
2013A$0.0461218.05%
2012A$0.0390723.9%
2011A$0.0315326.9%
2010A$0.0248512.37%
2009A$0.0221156.6%
2008A$0.014129.18%
2007A$0.01293114.48%
2006A$0.00603064.83%
2005A$0.00365935.55%
2004A$0.00269929.73%
2003A$0.00208119.86%
2002A$0.001736-2.71%
2001A$0.0017841.02%
2000A$0.001766